Of the 107 clinical-stage psychedelic drug stocks trading on North American stock exchanges (see here) 67 research the treatment of a variety of mental illnesses based on the use of 10 different psychedelic substances (see here) and 40 research the treatment of illnesses based on the use of THC marijuana. That being said, however, only 8 such companies have market caps of $50M or more, and trade for US$0.50/share or more, and they are tracked in the Psychedelic Compounds-Based Drug Stocks Index.

munKNEE Psychedelic Compounds-Based Drug Stocks Index

The constituent performances in July and YTD are presented below in descending order:

1. Compass Pathways (CMPS): UP 44% in July; DOWN 29.5% YTD
   • focused on the development of a new model of psilocybin therapy for people with treatment-resistant depression, in which psilocybin is administered in conjunction with psychological support.
2. Seelos (SEEL): UP 23.5% in July; DOWN 48.5% YTD
   • focused on developing products that address significant unmet needs in the Central Nervous System disorders and other rare disorders.
3. Allied Corp. (ALID): UP 14.6% in July; DOWN 68.9% YTD
   • focused on the research, development, and production of cannabinoid health solutions in the United States and has a product in a Phase I clinical trial in Columbia for treating post-traumatic stress disorder.
4. GH Resources (GHRS): UP 11.8% in July; DOWN 52.2% YTD
   • focused on developing novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.
5. Mind Medicine (MNMD): UP 7.8% in July; DOWN 50.0% YTD
   • focused on discovering, developing, and deploying the next generation of psychedelic-inspired medicines and therapies to address addiction and mental illness development.
6. Atai (ATAI): UP 6.0% in July; DOWN 49.4% YTD
   • focused on acquiring and efficiently developing innovative treatments that address significant unmet medical needs and lead to paradigm shifts in the mental health space.
7. Cybin (CYBN): UP 5.4% in July; DOWN 50.8% YTD 
   • focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.
8. Zynerba (ZYNE): No Change in July; DOWN 60.4% YTD
   • focused on developing and commercializing proprietary next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery.

In total, the munKNEE Psychedelic Compounds-Based Drug Stocks Index was UP 23.2% in July but is still DOWN 44.4% YTD.

More By This Author:

July Update: Plant-Based Food Stocks Index Up 19%: -51% YTD
Marijuana ETFs: Which One Is Right For You?
The 13 Largest American Cannabis MSOs: A Financial Assessment